Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: J Pathol. 2015 Jul 14;237(3):285–295. doi: 10.1002/path.4574

Figure 2.

Figure 2

Ablation of CD47 mitigates splenomegaly and antibody deposition in CD47−/−Faslpr mice. A–B) Photographs and weight comparison (n=7) of spleens from WT, CD47−/−, Faslpr and CD47−/−Faslpr mice at 8 months. C) Splenocyte numbers in WT, Faslpr and CD47−/−Faslpr mice (n=7). D–F) Kinetics of total serum IgG level (D), serum ANA level (E) and serum anti-dsDNA antibody level (F) in WT, CD47−/−, Faslpr and CD47−/−Faslpr mice (n=7).